US7301021B2
(en)
|
1997-07-02 |
2007-11-27 |
Smithkline Beecham Corporation |
Substituted imidazole compounds
|
EP1028953A1
(en)
*
|
1997-11-03 |
2000-08-23 |
Boehringer Ingelheim Pharmaceuticals Inc. |
Aromatic heterocyclic compounds as anti-inflammatory agents
|
EP1473292A1
(en)
*
|
1997-11-03 |
2004-11-03 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Aromatic heterocyclic compounds as anti-inflammatory agents
|
CZ299836B6
(cs)
*
|
1997-12-22 |
2008-12-10 |
Bayer Corporation |
Aryl- a heteroaryl-substituované heterocyklické mocoviny, jejich použití a farmaceutické kompozice s jejich obsahem
|
ES2154253T3
(es)
*
|
1997-12-22 |
2012-01-27 |
Bayer Healthcare Llc |
Inhibición de la actividad de p38 cinasa usando ureas heterocíclicas sustituidas.
|
SI1140840T1
(sl)
*
|
1999-01-13 |
2006-06-30 |
Bayer Pharmaceuticals Corp |
Omega-karboksiarilno substituirane difenil secnine kot inhibitorji raf kinaze
|
US8124630B2
(en)
|
1999-01-13 |
2012-02-28 |
Bayer Healthcare Llc |
ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
|
WO2000042012A1
(en)
*
|
1999-01-13 |
2000-07-20 |
Bayer Corporation |
φ-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS
|
EP1158985B1
(en)
|
1999-01-13 |
2011-12-28 |
Bayer HealthCare LLC |
OMEGA-CARBOXY ARYL SUBSTITUTED DIPHENYL UREAS AS p38 KINASE INHIBITORS
|
UA73492C2
(en)
*
|
1999-01-19 |
2005-08-15 |
|
Aromatic heterocyclic compounds as antiinflammatory agents
|
WO2000050425A1
(en)
|
1999-02-22 |
2000-08-31 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Polycyclo heterocyclic derivatives as antiinflammatory agents
|
SI1165516T1
(en)
|
1999-03-12 |
2005-02-28 |
Boehringer Ingelheim Pharmaceuticals Inc. |
Heterocyclic urea and related compounds useful as anti-inflammatory agents
|
JP2002539206A
(ja)
*
|
1999-03-12 |
2002-11-19 |
ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド |
抗炎症剤としての芳香族複素環化合物
|
ES2253233T3
(es)
|
1999-07-09 |
2006-06-01 |
Boehringer Ingelheim Pharmaceuticals Inc. |
Procedimiento para sintesis de compuestos de urea heteroaril sustituidos.
|
DE60036726T2
(de)
|
1999-11-16 |
2008-02-07 |
Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield |
Harnstoff derivate als entzündungshemmende mittel
|
ATE281439T1
(de)
|
1999-11-23 |
2004-11-15 |
Smithkline Beecham Corp |
3,4-dihydro-(1h)chinazolin-2-on-verbindungen als csbp/p38-kinase-inhibitoren
|
US6525046B1
(en)
|
2000-01-18 |
2003-02-25 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Aromatic heterocyclic compounds as antiinflammatory agents
|
US6608052B2
(en)
|
2000-02-16 |
2003-08-19 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Compounds useful as anti-inflammatory agents
|
WO2001070695A1
(en)
*
|
2000-03-22 |
2001-09-27 |
Vertex Pharmaceuticals Incorporated |
Pyridine derivatives as inhibitors of p38
|
US6645990B2
(en)
|
2000-08-15 |
2003-11-11 |
Amgen Inc. |
Thiazolyl urea compounds and methods of uses
|
EP1506962B1
(en)
|
2000-10-20 |
2008-07-02 |
Eisai R&D Management Co., Ltd. |
Nitrogen-containing aromatic heterocycles
|
EP1341771A2
(en)
|
2000-11-29 |
2003-09-10 |
Glaxo Group Limited |
Benzimidazole derivatives useful as tie-2 and/or vegfr-2 inhibitors
|
US6949567B2
(en)
|
2001-02-26 |
2005-09-27 |
4Sc Ag |
Compounds for the treatment of protozoal diseases
|
DE10109204A1
(de)
*
|
2001-02-26 |
2002-09-19 |
4Sc Ag |
Verbindungen zur Behandlung von Protozoen-Erkrankungen
|
WO2002092576A1
(en)
|
2001-05-16 |
2002-11-21 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Diarylurea derivatives useful as anti-inflammatory agents
|
JP2004531571A
(ja)
|
2001-05-25 |
2004-10-14 |
ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド |
サイトカイン生産のインヒビターとしてのカルバメート及びオキサミド化合物
|
JP4424983B2
(ja)
|
2001-06-05 |
2010-03-03 |
ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド |
1,4−ジ置換ベンゾ−縮合シクロアルキルウレア化合物
|
AU2002316459A1
(en)
|
2001-07-11 |
2003-01-29 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Methods of treating cytokine mediated diseases
|
WO2003032989A1
(en)
|
2001-10-18 |
2003-04-24 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
1,4-disubstituted benzo-fused urea compounds as cytokine inhibitors
|
DE10203086A1
(de)
*
|
2002-01-28 |
2003-07-31 |
Bayer Ag |
5-Ring Heterozyklen
|
WO2003068228A1
(en)
|
2002-02-11 |
2003-08-21 |
Bayer Pharmaceuticals Corporation |
Aryl ureas with angiogenesis inhibiting activity
|
AU2003210969A1
(en)
*
|
2002-02-11 |
2003-09-04 |
Bayer Corporation |
Aryl ureas with raf kinase and angiogenesis inhibiting activity
|
ATE529406T1
(de)
|
2002-02-11 |
2011-11-15 |
Bayer Healthcare Llc |
Aryl-harnstoffe als kinase inhibitoren
|
DE60319066T2
(de)
|
2002-02-25 |
2009-02-26 |
Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield |
1,4-disubstituierte benzokondensierte cycloalkyl-harnstoffverbindungen zur behandlung von zytokinvermittelten erkrankungen
|
EP1707205A2
(en)
|
2002-07-09 |
2006-10-04 |
Boehringer Ingelheim Pharma GmbH & Co. KG |
Pharmaceutical compositions of anticholinergics and p38 kinase inhibitors in the treatment of respiratory diseases
|
EP1549621A1
(en)
|
2002-08-08 |
2005-07-06 |
Boehringer Ingelheim Pharmaceuticals Inc. |
Fluorinated phenyl-naphthalenyl-urea compounds as inhibitors of cytokines involved in inflammatory processes
|
US7268139B2
(en)
|
2002-08-29 |
2007-09-11 |
Scios, Inc. |
Methods of promoting osteogenesis
|
US7144911B2
(en)
|
2002-12-31 |
2006-12-05 |
Deciphera Pharmaceuticals Llc |
Anti-inflammatory medicaments
|
US7202257B2
(en)
|
2003-12-24 |
2007-04-10 |
Deciphera Pharmaceuticals, Llc |
Anti-inflammatory medicaments
|
CA2516931C
(en)
|
2003-02-28 |
2014-09-09 |
Bayer Pharmaceuticals Corporation |
Novel bicyclic urea derivatives useful in the treatment of cancer and other disorders
|
JP2006521345A
(ja)
*
|
2003-03-28 |
2006-09-21 |
ファルマシア・アンド・アップジョン・カンパニー・エルエルシー |
ニコチン性アセチルコリン受容体の正のアロステリック調節剤
|
GB0320244D0
(en)
*
|
2003-05-06 |
2003-10-01 |
Aventis Pharma Inc |
Pyrazoles as inhibitors of tumour necrosis factor
|
MXPA05012486A
(es)
|
2003-05-20 |
2006-07-03 |
Bayer Pharmaceuticals Corp |
Diaril ureas para enfermedades mediadas por pdgfr.
|
UA84156C2
(ru)
|
2003-07-23 |
2008-09-25 |
Байер Фармасьютикалс Корпорейшн |
Фторозамещённая омега-карбоксиарилдифенилмочевина для лечения и профилактики болезней и состояний
|
MXPA06002853A
(es)
|
2003-09-11 |
2006-06-14 |
Kemia Inc |
Inhibidores citoquina.
|
WO2005030091A2
(en)
|
2003-09-25 |
2005-04-07 |
Scios Inc. |
Stents and intra-luminal prostheses containing map kinase inhibitors
|
WO2005044788A1
(ja)
|
2003-11-11 |
2005-05-19 |
Eisai Co., Ltd. |
ウレア誘導体およびその製造方法
|
TW200530236A
(en)
|
2004-02-23 |
2005-09-16 |
Chugai Pharmaceutical Co Ltd |
Heteroaryl phenylurea
|
US20060211752A1
(en)
|
2004-03-16 |
2006-09-21 |
Kohn Leonard D |
Use of phenylmethimazoles, methimazole derivatives, and tautomeric cyclic thiones for the treatment of autoimmune/inflammatory diseases associated with toll-like receptor overexpression
|
EP2295426A1
(en)
|
2004-04-30 |
2011-03-16 |
Bayer HealthCare, LLC |
Substituted pyrazolyl urea derivatives useful in the treatment of cancer
|
US20060035893A1
(en)
|
2004-08-07 |
2006-02-16 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders
|
KR20070053205A
(ko)
|
2004-09-17 |
2007-05-23 |
에자이 알앤드디 매니지먼트 가부시키가이샤 |
의약 조성물
|
JP2008523072A
(ja)
|
2004-12-07 |
2008-07-03 |
ルーカス ファーマシューティカルズ, インコーポレイテッド |
タンパク質キナーゼの阻害剤
|
EP1828169A2
(en)
|
2004-12-07 |
2007-09-05 |
Locus Pharmaceuticals, Inc. |
Urea inhibitors of map kinases
|
US20080081833A1
(en)
*
|
2004-12-20 |
2008-04-03 |
Astrazeneca Ab |
Novel Pyrazole Derivatives And Their Use As Modulators Of Nicotinic Acetylcholine Receptors
|
JP5197016B2
(ja)
*
|
2004-12-23 |
2013-05-15 |
デシファラ ファーマスーティカルズ, エルエルシー |
酵素モジュレータ及び治療
|
PE20060777A1
(es)
|
2004-12-24 |
2006-10-06 |
Boehringer Ingelheim Int |
Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
|
EP1676574A3
(en)
|
2004-12-30 |
2006-07-26 |
Johnson & Johnson Vision Care, Inc. |
Methods for promoting survival of transplanted tissues and cells
|
GB0500435D0
(en)
*
|
2005-01-10 |
2005-02-16 |
Novartis Ag |
Organic compounds
|
NZ561178A
(en)
|
2005-03-07 |
2010-11-26 |
Bayer Schering Pharma Ag |
Pharmaceutical composition comprising an omega-carboxyaryl substituted diphenyl urea for the treatment of cancer
|
DE102005015253A1
(de)
*
|
2005-04-04 |
2006-10-05 |
Merck Patent Gmbh |
Pyrazolderivate
|
US9006240B2
(en)
|
2005-08-02 |
2015-04-14 |
Eisai R&D Management Co., Ltd. |
Method for assay on the effect of vascularization inhibitor
|
DE102005037499A1
(de)
*
|
2005-08-09 |
2007-02-15 |
Merck Patent Gmbh |
Pyrazolderivate
|
PE20070795A1
(es)
*
|
2005-10-28 |
2007-08-24 |
Lilly Co Eli |
Compuestos pirazol-urea-heterociclicos como inhibidores de cinasa
|
JP2009513649A
(ja)
*
|
2005-10-28 |
2009-04-02 |
イーライ リリー アンド カンパニー |
キナーゼ阻害剤
|
WO2007075650A2
(en)
*
|
2005-12-21 |
2007-07-05 |
Bayer Healthcare Ag |
Substituted pyrimidine derivatives useful in the treatment of cancer and other disorders
|
EP2036557B1
(en)
|
2006-05-18 |
2015-10-21 |
Eisai R&D Management Co., Ltd. |
Antitumor agent for thyroid cancer
|
CA2652926A1
(en)
|
2006-05-26 |
2007-12-06 |
Bayer Healthcare Llc |
Drug combinations with substituted diaryl ureas for the treatment of cancer
|
CN101511793B
(zh)
|
2006-08-28 |
2011-08-03 |
卫材R&D管理有限公司 |
针对未分化型胃癌的抗肿瘤剂
|
EP2134677B1
(en)
|
2006-12-20 |
2011-10-12 |
Bayer HealthCare LLC |
4-{4-[({3-tert-butyl-1-[3-(hydroxymethyl)phenyl]-1h-pyrazol-5-yl}carbamoyl)-amino]-3-chlorophenoxy}-n-methylpyridine-2-carboxamide as an inhibitor of the vegfr kinase for the treatment of cancer
|
EP2119707B1
(en)
|
2007-01-29 |
2015-01-14 |
Eisai R&D Management Co., Ltd. |
Composition for treatment of undifferentiated-type of gastric cancer
|
JP5396379B2
(ja)
|
2007-04-02 |
2014-01-22 |
エボテック・アーゲー |
ピリド−2−イル縮合複素環式化合物ならびにその組成物および使用
|
RU2009142851A
(ru)
|
2007-04-20 |
2011-05-27 |
ДЕСИФЕРА ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи (US) |
Ингибиторы киназы, пригодные для лечения миелопролиферативных заболеваний и других пролиферативных заболеваний
|
EP1992344A1
(en)
|
2007-05-18 |
2008-11-19 |
Institut Curie |
P38 alpha as a therapeutic target in pathologies linked to FGFR3 mutation
|
WO2009035949A2
(en)
*
|
2007-09-13 |
2009-03-19 |
Arete Therapeutics, Inc. |
Soluble epoxide hydrolase inhibitors
|
EP2218712B1
(en)
|
2007-11-09 |
2015-07-01 |
Eisai R&D Management Co., Ltd. |
Combination of anti-angiogenic substance and anti-tumor platinum complex
|
GB0818033D0
(en)
|
2008-10-02 |
2008-11-05 |
Respivert Ltd |
Novel compound
|
PE20110598A1
(es)
|
2008-10-02 |
2011-08-31 |
Respivert Ltd |
Inhibidores de las enzimas de proteina cinasa activadas por mitogeno p38
|
WO2010067130A1
(en)
|
2008-12-11 |
2010-06-17 |
Respivert Limited |
P38 map kinase inhibitors
|
BRPI0922572A2
(pt)
|
2008-12-17 |
2019-09-24 |
Scripps Research Inst |
método para cultivar células pluripotentes, cultura de células de mamífero pluripotentes, meio de cultura de célula, célula animal pluripotente isolada, e, método para aumentar a pluripotência de uma célula de mamífero.
|
GB0905955D0
(en)
|
2009-04-06 |
2009-05-20 |
Respivert Ltd |
Novel compounds
|
JP5787976B2
(ja)
|
2010-04-08 |
2015-09-30 |
レスピバート・リミテツド |
P38mapキナーゼ阻害剤としてのピラゾリルウレア
|
AU2011270165B2
(en)
|
2010-06-25 |
2015-12-24 |
Eisai R&D Management Co., Ltd. |
Antitumor agent using compounds having kinase inhibitory effect in combination
|
US20130183268A1
(en)
|
2010-07-19 |
2013-07-18 |
Bayer Healthcare Llc |
Drug combinations with fluoro-substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions
|
CN103402519B
(zh)
|
2011-04-18 |
2015-11-25 |
卫材R&D管理有限公司 |
肿瘤治疗剂
|
NZ618795A
(en)
*
|
2011-05-13 |
2015-07-31 |
Array Biopharma Inc |
Pyrrolidinyl urea, pyrrolidinyl thiourea and pyrrolidinyl guanidine compounds as trka kinase inhibitors
|
JP6038128B2
(ja)
|
2011-06-03 |
2016-12-07 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
レンバチニブ化合物に対する甲状腺癌対象及び腎臓癌対象の反応性を予測及び評価するためのバイオマーカー
|
EP2578582A1
(en)
|
2011-10-03 |
2013-04-10 |
Respivert Limited |
1-Pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl)oxy)napththalen-1-yl)ureas as p38 MAP kinase inhibitors
|
MY167798A
(en)
|
2011-10-03 |
2018-09-26 |
Respivert Ltd |
1-pyrazolyl-3- (4- ( (2 -anilinopyrimidin- 4 - yl) oxy) napththalen- 1 - yl) ureas as p38 map kinase inhibitors
|
EP2793880A4
(en)
*
|
2011-12-23 |
2015-06-24 |
Millennium Pharm Inc |
HETEROARYLE AND USES THEREOF
|
JP6218229B2
(ja)
|
2011-12-28 |
2017-10-25 |
京都府公立大学法人 |
角膜内皮細胞の培養正常化
|
JP6194517B2
(ja)
|
2012-04-27 |
2017-09-13 |
学校法人慶應義塾 |
神経分化促進剤
|
US8461179B1
(en)
|
2012-06-07 |
2013-06-11 |
Deciphera Pharmaceuticals, Llc |
Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
|
GB201214750D0
(en)
|
2012-08-17 |
2012-10-03 |
Respivert Ltd |
Compounds
|
GB201215357D0
(en)
|
2012-08-29 |
2012-10-10 |
Respivert Ltd |
Compounds
|
WO2014078325A1
(en)
|
2012-11-13 |
2014-05-22 |
Array Biopharma Inc. |
N-(monocyclic aryl),n'-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
|
NZ708028A
(en)
|
2012-11-13 |
2018-12-21 |
Array Biopharma Inc |
N-pyrrolidinyl, n’-pyrazolyl- urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
|
WO2014078372A1
(en)
|
2012-11-13 |
2014-05-22 |
Array Biopharma Inc. |
Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
|
WO2014078328A1
(en)
|
2012-11-13 |
2014-05-22 |
Array Biopharma Inc. |
N-bicyclic aryl,n'-pyrazolyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
|
WO2014078408A1
(en)
|
2012-11-13 |
2014-05-22 |
Array Biopharma Inc. |
Bicyclic heteroaryl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
|
WO2014078417A1
(en)
|
2012-11-13 |
2014-05-22 |
Array Biopharma Inc. |
Pyrazolyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
|
WO2014078322A1
(en)
|
2012-11-13 |
2014-05-22 |
Array Biopharma Inc. |
Thiazolyl and oxazolyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
|
US9969694B2
(en)
|
2012-11-13 |
2018-05-15 |
Array Biopharma Inc. |
N-(arylalkyl)-N′-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors
|
ES2610975T3
(es)
|
2012-11-13 |
2017-05-04 |
Array Biopharma, Inc. |
Compuestos bicíclicos de urea, tiourea, guanidina y cianoguanidina útiles para el tratamiento del dolor
|
WO2014078378A1
(en)
|
2012-11-13 |
2014-05-22 |
Array Biopharma Inc. |
Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
|
AU2013364953A1
(en)
|
2012-12-21 |
2015-04-30 |
Eisai R&D Management Co., Ltd. |
Amorphous form of quinoline derivative, and method for producing same
|
EP2970190A1
(en)
|
2013-03-14 |
2016-01-20 |
Respivert Limited |
Kinase inhibitors
|
MX368099B
(es)
|
2013-05-14 |
2019-09-19 |
Eisai R&D Man Co Ltd |
Biomarcadores para predecir y evaluar el grado de respuesta de sujetos con cancer de endometrio a compuestos de tipo lenvatinib.
|
US9750723B2
(en)
|
2013-10-31 |
2017-09-05 |
Ohio University |
Prevention and treatment of non-alcoholic fatty liver disease
|
WO2015072580A1
(ja)
|
2013-11-14 |
2015-05-21 |
学校法人同志社 |
細胞増殖促進または細胞障害抑制による角膜内皮治療薬
|
CN106164067B
(zh)
|
2014-02-14 |
2019-09-10 |
瑞斯比维特有限公司 |
作为抗炎化合物的芳族杂环化合物
|
UA122126C2
(uk)
|
2014-05-15 |
2020-09-25 |
Еррей Біофарма Інк. |
1-((3s,4r)-4-(3-фторфеніл)-1-(2-метоксіетил)піролідин-3-іл)-3-(4-метил-3-(2-метилпіримідин-5-іл)-1-феніл-1h-піразол-5-іл)сечовина як інгібітор trka-кінази
|
US10023567B2
(en)
|
2014-07-18 |
2018-07-17 |
Ohio University |
Imidazole and thiazole compositions for modifying biological signaling
|
PT3524595T
(pt)
|
2014-08-28 |
2022-09-19 |
Eisai R&D Man Co Ltd |
Derivado de quinolina altamente puro e método para produção do mesmo
|
SI3263106T1
(sl)
|
2015-02-25 |
2024-02-29 |
Eisai R&D Management Co., Ltd. |
Postopek zatiranja grenkobe derivata kinolina
|
AU2015384801B2
(en)
|
2015-03-04 |
2022-01-06 |
Eisai R&D Management Co., Ltd. |
Combination of a PD-1 antagonist and a VEGFR/FGFR/RET tyrosine kinase inhibitor for treating cancer
|
AU2016279474B2
(en)
|
2015-06-16 |
2021-09-09 |
Eisai R&D Management Co., Ltd. |
Anticancer agent
|
JP2021512105A
(ja)
|
2018-01-31 |
2021-05-13 |
デシフェラ・ファーマシューティカルズ,エルエルシー |
消化管間質腫瘍の治療のための併用療法
|
MA54133B1
(fr)
|
2018-03-08 |
2022-01-31 |
Incyte Corp |
Composés d'aminopyrazine diol utilisés comme inhibiteurs de pi3k-y
|
WO2019191032A1
(en)
|
2018-03-26 |
2019-10-03 |
Clear Creek Bio, Inc. |
Compositions and methods for inhibiting dihydroorotate dehydrogenase
|
US11046658B2
(en)
|
2018-07-02 |
2021-06-29 |
Incyte Corporation |
Aminopyrazine derivatives as PI3K-γ inhibitors
|
WO2021030405A1
(en)
|
2019-08-12 |
2021-02-18 |
Deciphera Pharmaceuticals, Llc |
Ripretinib for treating gastrointestinal stromal tumors
|
BR112022002609A2
(pt)
|
2019-08-12 |
2022-08-09 |
Deciphera Pharmaceuticals Llc |
Métodos de tratamento de tumores estromais gastrointestinais
|
SI4084778T1
(sl)
|
2019-12-30 |
2024-01-31 |
Deciphera Pharmaceuticals, Llc |
Formulacije inhibitorja amorfne kinaze in načini njihove uporabe
|
IL293864A
(en)
|
2019-12-30 |
2022-08-01 |
Deciphera Pharmaceuticals Llc |
Preparations of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl)-3- phenylurea
|
US11779572B1
(en)
|
2022-09-02 |
2023-10-10 |
Deciphera Pharmaceuticals, Llc |
Methods of treating gastrointestinal stromal tumors
|